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Abstract
Health Issue: The incidence of bacterial sexually transmitted infections (STIs) is rising in Canada.
If these curable infections were prevented and treated, serious long-term sequelae including
infertility, and associated treatment costs, could be dramatically reduced. STIs pose a greater risk
to women than men in many ways, and further gender differences exist in screening and diagnosis.
Key Findings: Reported incidence rates of chlamydia, gonorrhea, and infectious syphilis declined
until 1997, when the trend began to reverse. The reported rate of chlamydia is much higher among
women than men, whereas the reverse is true for gonorrhea and infectious syphilis. Increases in
high-risk sexual behaviour among men who have sex with men were observed after the
introduction of potent HIV suppressive therapy in 1996, but behavioural changes in women await
further research.
Data Gaps and Recommendations: STI surveillance in Canada needs improvement. Reported
rates underestimate the true incidence. Gender-specific behavioural changes must be monitored
to enhance responsiveness to groups at highest risk, and more research is needed on effective
strategies to promote safer sexual practices. Geographic and ethnic disparities, gaps, and needs
must be addressed. Urine screening for chlamydia should be more widely available for women as
well as men, particularly among high-risk men in order to prevent re-infections in their partners.
As women are more likely to present for health examinations (e.g. Pap tests), these screening
opportunities must be utilized. Female-controlled methods of STI prevention, such as safer topical
microbicides, are urgently needed.
Background
The incidence of sexually transmitted infections (STIs),
such as chlamydia, gonorrhea and syphilis, is rising in
Canada, with serious health and economic consequences.
Women are at greater risk of STIs than men in a number
of ways, including their susceptibility to infection and the
severity of the sequelae associated with infection. A fur-
ther difference between men and women lies in the
difficulties involved in screening and diagnosis. This
chapter discusses these differences and presents
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surveillance data on the incidence of chlamydia, gonor-
rhea and syphilis.
STI Susceptibility and Transmission
A female in early adolescence is at increased risk of STIs,
because her cervical os still comprises an exposed squa-
mocolumnar junction, which during puberty is gradually
replaced by squamous tissue[1]. Squamous cells are resist-
ant to chlamydia and gonorrhea, whereas columnar epi-
thelium supports their growth. As well, in early
adolescence the cervical mucus, which is normally protec-
tive, is more easily penetrated by these organisms[2]. Oral
contraceptive pills (OCPs) increase vulnerability to STIs in
females of any age by enlarging the size of this squamoco-
lumnar junction [3-6]. but may. protect against pelvic
inflammatory disease (PID), a serious consequence of
STIs [6-9].
Little is known about biological susceptibility factors in
males, except that circumcision reduces the risk of STIs,
including infection with human papillomavirus (HPV)
[10-19]. Circumcision in men at high risk of HPV also
reduces the risk of cervical cancer in their female
partners[20].
Many STIs are transmitted more efficiently from males to
females. For example, the risk of genital herpes transmis-
sion from a male to female partner is 19%, whereas it is
5% for transmission from female to male[21]. After a sin-
gle episode of sexual intercourse, a woman has a 60% to
90% chance of contracting gonorrhea from her infected
male partner, whereas the risk for a man from a woman is
20% to 30%[22,23]. The reasons for this difference may
include greater exposure in females as a result of pooled
semen in the vagina and greater trauma to tissues during
intercourse.
Sequelae
Once infected, women face a disproportionate burden of
sequelae from STIs. These include PID, chronic pelvic
pain, ectopic pregnancy, infertility and cervical cancers.
After one episode of PID, 20% of females will suffer
chronic pelvic pain, 9% an ectopic pregnancy and 8%
infertility; the risk of infertility doubles after each subse-
quent episode[24]. PID is the cause of 15% of all infertil-
ity. In men, infertility is only a very rare complication of
STIs. Although HPV rarely causes penile and anal cancers
in males, females may develop the much more common
cervical as well as vaginal and anal cancers[25]. If a preg-
nant woman is infected, the STI can be transmitted to her
newborn, and may result in miscarriage, premature
labour, stillbirth, mental retardation and infant
death[26].
Screening, Diagnosis and Treatment
For gonorrhea, up to 80% of females can be asympto-
matic, as compared with about 10% to 20% of men[27].
Thus, females are more likely than males to harbour this
infection, and it is likely to remain undiagnosed.
Although 80% of women with chlamydia remain asymp-
tomatic, half of men with chlamydia have symp-
toms[28,29]. Screening is critical to reducing the size of
this hidden epidemic. Indeed, a randomized controlled
trial of chlamydia screening demonstrated a reduction in
the incidence of PID[30].
Clinical diagnosis of STIs in females is not as reliable as in
males because invasive pelvic examinations are required
and because vaginal discharge may be due to non-sexually
transmitted diseases. As well, laboratory detection of an
STI in genital specimens from women is more difficult:
the sensitivity and specificity of the tests used may be
affected by the presence of blood, mucus or organisms
normally present in the body[31].
Males may be less likely to attend for screening, as collect-
ing a urethral swab might be a deterrent. STI recurrences
in females have been associated with an infected male
partner who either keeps the infection secret or whose
condition remains undiagnosed and untreated. Chlamy-
dia screening programs have traditionally targeted only
females. Ironically, if active screening of the infection in
men were increased this would benefit women by reduc-
ing their reinfection rate and sending the message that
men must take responsibility for sexual and reproductive
matters. The recent introduction of non-invasive urine-
based nucleic acid diagnostic tests, which may be carried
out in or outside the health care setting, has overcome cer-
tain diagnostic challenges in both males and females [32-
38], and these tests may prove less of a deterrent to screen-
ing in men.
As settings of both prevention and treatment, STD clinics
have been less sensitive to the needs of women, whereas
family planning programs have focused less on the needs
of men[39]. Men are more likely than women to be
screened for syphilis when an STI is suspected[40].
Women are more likely to treat themselves, using over-
the-counter vaginal yeast medications, douches, etc.,
which can mask an actual STI and delay diagnosis[39,41].
Methods
Chlamydia, gonorrhea and syphilis infections are nation-
ally notifiable bacterial STIs in Canada. All 13 provinces
and territories provide Health Canada with non-nominal
surveillance data consisting of at least age or age group,
sex, and province or territory of residence.BMC Women's Health 2004, 4:S26 http://www.biomedcentral.com/1472-6874/4/S1/S26
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Surveillance data submitted to Health Canada from 1991
to 2000 (From 1993 infectious syphilis (primary, second-
ary and early latent syphilis) was introduced to replace
early symptomatic syphilis; chlamydia data were reported
only from 1992 by some jurisdictions were analyzed. The
data for 2000 are preliminary, and changes for this year
are anticipated because of reporting delays. Annual inci-
dence rates per 100,000 population were calculated using
census population estimates and intercensus estimates
from Statistics Canada. The chi-square test was used for
comparison of proportions, and the chi-square test for
trends was used to compare proportion trends. A two-
sided p value of less than 0.05 was considered to indicate
statistical significance.
Results
Chlamydia (Figures 1 and 2)
Females accounted for over two thirds of the 46,000
chlamydia cases reported in Canada, at a rate of 211.8 per
100,000 versus 89.1 per 100,000 among men in the year
2000 (p < 0.001). The chlamydia rate had been on the
decline until 1997, when this downward trend started to
revert (Figure 1). Since then, the rate has increased signif-
icantly among both males (p < 0.001) and females (p <
0.001), with a greater increase in males (53.4% versus
27.4%, p <0.001). The highest incidence and fastest rate
of increase has been in the 15 to 24 age group among
females but in the 20s age group among males.
Gonorrhea (Figures 3 and 4)
Males accounted for almost two thirds of the 6,000
nationally reported cases of gonorrhea in the year 2000, at
a rate of 25.3 per 100,000 versus 15.3 per 100,000 among
females (p < 0.001). The gonorrhea rate had been on the
decline until 1997, when it began to increase again (Fig-
ure 2). Since then, the rate has increased significantly
Reported Chlamydia Rate per 100,000 Population in Canada, 1997–2000 Figure 1
Reported Chlamydia Rate per 100,000 Population in Canada, 1997–2000 Source: Sexual Health and Sexually Trans-
mitted Infections, Centre for Infectious Disease Prevention and Control, Health Canada, 2001
Reported Chlamydia Rates in Canada Figure 2
Reported Chlamydia Rates in Canada Source: Sexual 
Health and Sexually Transmitted Infections, Centre for Infec-
tious Disease Prevention and Control, Health Canada, 2001BMC Women's Health 2004, 4:S26 http://www.biomedcentral.com/1472-6874/4/S1/S26
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among both males (p < 0.001) and females (p = 0.02), but
with a greater increase among males (42.9% versus
31.9%, p = 0.002). Among females, the peak incidence
and the fastest rate of increase have taken place in the 15
to 24 age group. The highest reported incidence among
males has been in the 20 to 29 age group and the fastest
rate of increase in the 20s and 30s age groups.
Syphilis (Figures 5 and 6)
Males made up almost two thirds of the 171 cases of infec-
tious syphilis reported nationally in the year 2000, at a
rate of 0.73 per 100,000 versus 0.39 per 100,000 among
females (p < 0.001). The infectious syphilis rate had been
on the decline until 1997, when this downward trend
started to revert (Figure 3). Since then, the rate has
increased significantly among males, by 62.2% (p <
0.001), but not among females (p = 0.3). The peak
incidence among females occurred in 15 to 39 year olds
and the fastest rate of increase in the 15 to 24 age group.
The highest incidence and fastest increase among males
have occurred in the 25 to 29 age group.
Discussion
STI
Since 1996, molecular diagnostic testing for chlamydia
has become increasingly available across Canada. These
tests have the advantage of being non-invasive and more
sensitive than the older methodologies used for the diag-
nosis of chlamydia. In addition, the increasing availability
Reported Gonorrhea Rate per 100,000 Population in Canada, 1997 to 2000 Figure 3
Reported Gonorrhea Rate per 100,000 Population in Canada, 1997 to 2000. Source: Sexual Health and Sexually 
Transmitted Infections, Centre for Infectious Disease Prevention and Control, Health Canada, 2001
Reported Gonorrhea Rates in Canada Figure 4
Reported Gonorrhea Rates in Canada Source: Sexual 
Health and Sexually Transmitted Infections, Centre for Infec-
tious Disease Prevention and Control, Health Canada, 2001BMC Women's Health 2004, 4:S26 http://www.biomedcentral.com/1472-6874/4/S1/S26
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of urine-based tests has made testing for chlamydia more
acceptable for both men and women. This, along with
recent improvements in chlamydia screening initiatives,
may have contributed to the observed increase in reported
chlamydia incidence.
Since the introduction of these tests, there has been a con-
sistent upswing in reported rates not only of chlamydia
but also of gonorrhea and syphilis, despite the lack of
widespread screening and diagnostic advances for these
latter infections in Canada. In the absence of
improvement in disease reporting, this is strongly sugges-
tive of real increases in the occurrence of these STIs in
recent years.
Sexual Behaviours
Although STI rates had been declining since the beginning
of the HIV epidemic – possibly as a result of prevention
and screening programs, changes in sexual behaviour in
response to the HIV epidemic, and the availability of sin-
gle-dose treatment for some STIs[42,43] – the decline. was
reversed in 1997. Increases in high-risk sexual behaviour
in men who have sex with men were reported after the
introduction of potent, antiretroviral HIV suppressive
therapy [44-47], but behavioural changes in women await
further research.
Girls and boys are socialized into different gender roles,
affected by culture, peer and parental influences. Males
tend to have an earlier sexual debut and a higher rate of
partner changes[39,48]. Females are more likely than
males to have been forced into their first sexual
encounter[49]. Men have more control than women over
condom use. Women are uncomfortable about insisting
on condom use for fear of the reactions of their male part-
ners regarding trust and commitment issues[50,51]. The
power differential and potential for domestic violence cre-
ate barriers that may prevent women from protecting
themselves[52]. Therefore, prevention programs for
women need to target safer sex negotiation skills and
female-controlled methods[53,54].
Reported Infectious Syphilis Rate per 100,000 Population in Canada, 1997 to 2000 Figure 5
Reported Infectious Syphilis Rate per 100,000 Population in Canada, 1997 to 2000 Source: Sexual Health and Sexu-
ally Transmitted Infections, Centre for Infectious Disease Prevention and Control, Health Canada, 2001
Reported Infectious Syphlis Rates in Canada Figure 6
Reported Infectious Syphlis Rates in Canada Source: 
Sexual Health and Sexually Transmitted Infections, Centre 
for Infectious Disease Prevention and Control, Health Can-
ada, 2001BMC Women's Health 2004, 4:S26 http://www.biomedcentral.com/1472-6874/4/S1/S26
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Prevention
In a U.S. survey of 1,000 females, only 11% were aware of
the fact that STIs are more harmful to females than to
males; those with less knowledge were less likely to prac-
tise safer sex[39]. Preventive information is necessary for
behaviour to change, but it is not sufficient. Most preven-
tion programs have been proven to fail. Issues specific to
gender and culture must be incorporated. Women benefit
from prevention strategies that address gender roles, the
power differential between the sexes, financial depend-
ence on men, fulfillment in their intimate relationships,
and bonding with other women [55-57]. Two
randomized controlled trials incorporating these ele-
ments showed a significant reduction in rates of
STIs[58,59].
Economic Burden
In 1990, the estimated direct and indirect costs of chlamy-
dia in Canadian females, including diagnosis, treatment
and productivity loss, were as high as $115 million (Cana-
dian) dollars; for males the cost was as high as $8 million.
In the same year, the cost burden of gonorrhea was up to
$63 million for females and $12 million for males[60]. If
properly prevented and treated, the cost savings would be
enormous for these easily curable illnesses.
Data Limitations
The reported rate for any disease may underestimate the
true incidence if a lack of symptoms causes people not to
present themselves for diagnosis. Up to 80% of women
with gonorrhea or chlamydia can be asymptomatic, and
discharge and genital lesions are harder to detect and diag-
nose in women. In general, men do not go for screening
or medical examination as regularly as women and, even
if they do, clinicians may not screen them for STIs if they
are asymptomatic. Therefore, undiagnosed chlamydia in
men may contribute in part to the significantly lower
reported rate among men. Thus the reported rates are a
fraction of the true disease burden, and they are influ-
enced by the amount of screening.
Policy Implications and Recommendations
The highest public health priority is to reduce this hidden
epidemic in youth, the group burdened with the highest
infection rate. Young women are more susceptible to STIs
than young men, and more likely to have hidden infec-
tions, resulting in longer diagnostic and treatment delays
and the development of long-term sequelae. Health
professionals should be encouraged to provide preven-
tion and care services that are evidence-based, gender-spe-
cific and culturally sensitive. To reduce the health and
economic consequences of the increasing rates of STIs,
action must be taken in the following areas.
Surveillance
• Strengthen the STI surveillance system across Canada,
especially in high-risk subpopulations.
• Assess gender, ethnic (e.g. Aboriginal people) and geo-
graphic disparities (e.g. rural versus urban).
Research
• Evaluate gender-specific behavioural changes leading to
increased STI rates.
• Evaluate safer, acceptable and female-controlled meth-
ods of STI prevention, such as topical microbicides, that
do not increase the risk of HIV transmission[61].
• Evaluate gender-specific strategies that promote safer
sexual practices and behaviour change, such as the use of
the Internet for STI/HIV "cyberprevention."
Prevention
• Develop gender-specific strategies that address biologi-
cal, socio-demographic, access, prevention, screening and
behavioural issues[62].
• Increase availability of urine screening for chlamydia.
• Improve urine screening test performance for
gonorrhea.
• Increase prevention efforts targeting the high disease
burden of chlamydia, particularly through screening of
youth and disenfranchised populations as well as of
women and men at high risk.
• Increase opportunities for screening by taking advantage
of women's greater tendency to present for health exami-
nations (e.g. Pap tests).
• Adopt creative approaches to screening in men, in order
to prevent reinfection in their female partners.
Note
The views expressed in this report do not necessarily rep-
resent the views of the Canadian Population Health Initi-
ative, the Canadian Institute for Health Information or
Health Canada.
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